{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:11:11Z","timestamp":1789056671891,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>MicroRNAs (miRs), small noncoding RNAs that regulate gene expression post-transcriptionally, have been shown to vary in their expression throughout CKD stages, dialysis modality, alterations in left ventricular hypertrophy, vascular tone, and inflammation. In addition, fluctuations in miR expression have been reported with various hemodialysis regimens, although whether these alterations contribute mechanistically to the observed clinical effects remains unresolved. The relative stability of miRs in biologic fluids offers an opportunity for the identification of biomarkers for disease monitoring and assessing for therapeutic intervention. We will review the current understanding of miR regulation within the context of dialysis, to better define the molecular impact of conventional and intensive hemodialysis and guide the development of targeted strategies to mitigate CKD-related complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000001002","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T17:00:20Z","timestamp":1768237220000},"page":"1638-1644","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Role of MicroRNA Regulation on Clinical Outcomes in Kidney Disease"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1431-8198","authenticated-orcid":false,"given":"Carmine A.","family":"Alberga","sequence":"first","affiliation":[{"name":"Department of Physiology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Peter Munk Cardiac Center, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-1215","authenticated-orcid":false,"given":"Filio","family":"Billia","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Peter Munk Cardiac Center, University Health Network, Toronto, Ontario, Canada"},{"name":"Ted Rogers Center for Heart Research, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-7273","authenticated-orcid":false,"given":"Christopher T.","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"2","key":"B1-20260910","doi-asserted-by":"crossref","first-page":"205","DOI":"10.34067\/KID.0000000000000360","article-title":"Cardiovascular outcomes in patients on home hemodialysis and peritoneal dialysis","volume":"5","author":"Shah","year":"2024","journal-title":"Kidney360."},{"issue":"2","key":"B2-20260910","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCIMAGING.111.969923","article-title":"Determinants of left ventricular mass in patients on hemodialysis: the frequent hemodialysis network (FHN) trials","volume":"5","author":"Chan","year":"2012","journal-title":"Circ Cardiovasc Imaging."},{"issue":"9","key":"B3-20260910","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1681\/ASN.2005040392","article-title":"Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study","volume":"16","author":"Ayus","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B4-20260910","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.0000000000000299","article-title":"Update on hemodialysis-induced multiorgan ischemia","volume":"35","author":"McIntyre","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B5-20260910","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12882-017-0483-z","article-title":"Ultrafiltration rate is an important determinant of microcirculatory alterations during chronic renal replacement therapy","volume":"18","author":"Veenstra","year":"2017","journal-title":"BMC Nephrol."},{"issue":"1","key":"B6-20260910","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2215\/CJN.03170707","article-title":"Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow","volume":"3","author":"McIntyre","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B7-20260910","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.03900808","article-title":"Hemodialysis-induced cardiac injury: determinants and associated outcomes","volume":"4","author":"Burton","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"suppl 2","key":"B8-20260910","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/ndt\/gfaa020","article-title":"Using more frequent haemodialysis to manage volume overload in dialysis patients with heart failure, obesity or pregnancy","volume":"35","author":"Sangala","year":"2020","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B9-20260910","first-page":"1730","article-title":"Serum microRNA profiles in patients with autosomal dominant polycystic kidney disease show systematic dysregulation partially reversible by hemodialysis","volume":"17","author":"Ma\u0142achowska","year":"2021","journal-title":"Arch Med Sci."},{"issue":"1","key":"B10-20260910","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1038\/s41598-019-41101-8","article-title":"Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients","volume":"9","author":"Fourdinier","year":"2019","journal-title":"Sci Rep."},{"issue":"23","key":"B11-20260910","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.3390\/cancers13235874","article-title":"The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers","volume":"13","author":"Cavallari","year":"2021","journal-title":"Cancers."},{"key":"B12-20260910","doi-asserted-by":"crossref","first-page":"1283597","DOI":"10.3389\/fphys.2023.1283597","article-title":"Advances in the study of miRNAs in chronic kidney disease with cardiovascular complications","volume":"14","author":"Zou","year":"2023","journal-title":"Front Physiol."},{"issue":"12","key":"B13-20260910","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nat Rev Genet."},{"issue":"1","key":"B14-20260910","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell."},{"issue":"3","key":"B15-20260910","doi-asserted-by":"crossref","first-page":"e1627","DOI":"10.1002\/wrna.1627","article-title":"MicroRNA strand selection: unwinding the rules","volume":"12","author":"Medley","year":"2021","journal-title":"Wiley Interdiscip Rev RNA."},{"issue":"1","key":"B16-20260910","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molcel.2021.11.026","article-title":"Life of RISC: formation, action, and degradation of RNA-induced silencing complex","volume":"82","author":"Iwakawa","year":"2022","journal-title":"Mol Cell."},{"issue":"3","key":"B17-20260910","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/diagnostics11030421","article-title":"Circulating MicroRNAs in blood and other body fluids as biomarkers for diagnosis, prognosis, and therapy response in lung cancer","volume":"11","author":"Gayosso-G\u00f3mez","year":"2021","journal-title":"Diagnostics."},{"issue":"9","key":"B18-20260910","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/biomedicines11092358","article-title":"The role of miRNA in renal fibrosis leading to chronic kidney disease","volume":"11","author":"Gluba-Sagr","year":"2023","journal-title":"Biomedicines."},{"issue":"3","key":"B19-20260910","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11255-021-02922-7","article-title":"miRNA biomarkers in renal disease","volume":"54","author":"Franczyk","year":"2022","journal-title":"Int Urol Nephrol."},{"key":"B20-20260910","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3389\/fcell.2020.00739","article-title":"Inflammation, senescence and MicroRNAs in chronic kidney disease","volume":"8","author":"Carmona","year":"2020","journal-title":"Front Cell Dev Biol."},{"issue":"6","key":"B21-20260910","doi-asserted-by":"crossref","first-page":"e38269","DOI":"10.1371\/journal.pone.0038269","article-title":"Circulating MicroRNAs are not eliminated by hemodialysis","volume":"7","author":"Martino","year":"2012","journal-title":"PLoS One."},{"issue":"7","key":"B22-20260910","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbadis.2014.03.005","article-title":"miR-223: an inflammatory oncomiR enters the cardiovascular field","volume":"1842","author":"Ta\u00efbi","year":"2014","journal-title":"Biochim Biophys Acta."},{"issue":"8","key":"B23-20260910","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.1800747","article-title":"Online hemodiafiltration inhibits inflammation-related endothelial dysfunction and vascular calcification of uremic patients modulating miR-223 expression in plasma extracellular vesicles","volume":"202","author":"Cavallari","year":"2019","journal-title":"J Immunol."},{"issue":"12","key":"B24-20260910","doi-asserted-by":"crossref","first-page":"e0244065","DOI":"10.1371\/journal.pone.0244065","article-title":"A strategic expression method of miR-29b and its anti-fibrotic effect based on RNA-sequencing analysis","volume":"15","author":"Fan","year":"2020","journal-title":"PLoS One."},{"issue":"2","key":"B25-20260910","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/ijms25021132","article-title":"Modulation of miR-29a and miR-29b expression and their target genes related to inflammation and renal fibrosis by an oral nutritional supplement with probiotics in malnourished hemodialysis patients","volume":"25","author":"Sasso","year":"2024","journal-title":"Int J Mol Sci."},{"issue":"1","key":"B26-20260910","first-page":"8","article-title":"Comparative analysis of patients\u2019 survival on hemodialysis vs. peritoneal dialysis and identification of factors associated with death","volume":"45","author":"Vicentini","year":"2023","journal-title":"J Bras Nefrol."},{"issue":"2\u20103","key":"B27-20260910","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000521508","article-title":"Comparative effectiveness of dialysis modality on laboratory parameters of mineral metabolism","volume":"53","author":"Soohoo","year":"2022","journal-title":"Am J Nephrol."},{"issue":"1","key":"B28-20260910","doi-asserted-by":"crossref","first-page":"135","DOI":"10.23876\/j.krcp.20.153","article-title":"Changes in extracellular water and left ventricular mass in peritoneal dialysis patients","volume":"40","author":"Tangwonglert","year":"2021","journal-title":"Kidney Res Clin Pract."},{"issue":"5","key":"B29-20260910","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/biom10050768","article-title":"Unfavorable effects of peritoneal dialysis solutions on the peritoneal membrane: the role of oxidative stress","volume":"10","author":"Roumeliotis","year":"2020","journal-title":"Biomolecules."},{"issue":"11","key":"B30-20260910","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc Res."},{"issue":"11","key":"B31-20260910","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.298.11.1291","article-title":"Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of LifeA randomized controlled trial","volume":"298","author":"Culleton","year":"2007","journal-title":"JAMA."},{"issue":"12","key":"B32-20260910","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2215\/CJN.03280313","article-title":"Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling","volume":"8","author":"Chan","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B33-20260910","doi-asserted-by":"crossref","first-page":"12694","DOI":"10.1038\/s41598-021-91431-9","article-title":"Exploring the relation between mortality and left ventricular structure and function in stable hemodialysis treated patients, a longitudinal multicenter cohort study","volume":"11","author":"Chisavu","year":"2021","journal-title":"Sci Rep."},{"issue":"6","key":"B34-20260910","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MNH.0000000000000067","article-title":"Is left ventricular hypertrophy a modifiable risk factor in ESRD","volume":"23","author":"Charytan","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"7","key":"B35-20260910","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3390\/biomedicines12071547","article-title":"The clinical significance and application of heart rate variability in dialysis patients: a narrative review","volume":"12","author":"Jhen","year":"2024","journal-title":"Biomedicines."},{"issue":"6","key":"B36-20260910","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/toxins13060380","article-title":"Expanded haemodialysis as a current strategy to remove uremic toxins","volume":"13","author":"Ciceri","year":"2021","journal-title":"Toxins."},{"issue":"1","key":"B37-20260910","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1570161118666200401112106","article-title":"Cardiovascular benefits of extended-time nocturnal hemodialysis","volume":"19","author":"Roumeliotis","year":"2021","journal-title":"Curr Vasc Pharmacol."},{"issue":"8","key":"B38-20260910","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics \u2014 challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat Rev Drug Discov."},{"key":"B39-20260910","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","article-title":"miR-34 \u2013 a microRNA replacement therapy is headed to the clinic","volume":"3","author":"Bader","year":"2012","journal-title":"Front Genet."},{"key":"B40-20260910","doi-asserted-by":"crossref","first-page":"640587","DOI":"10.3389\/fcell.2021.640587","article-title":"MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol."},{"issue":"8","key":"B41-20260910","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/nar\/gkl183","article-title":"Improved targeting of miRNA with antisense oligonucleotides","volume":"34","author":"Davis","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"B42-20260910","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"19","key":"B43-20260910","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/cells11193117","article-title":"In vivo inhibition of miR-34a modestly limits cardiac enlargement and fibrosis in a mouse model with established type 1 diabetes-induced cardiomyopathy, but does not improve diastolic function","volume":"11","author":"Bernardo","year":"2022","journal-title":"Cells."},{"issue":"10","key":"B44-20260910","doi-asserted-by":"crossref","first-page":"e138027","DOI":"10.1172\/jci.insight.138027","article-title":"MicroRNA-30 regulates left ventricular hypertrophy in chronic kidney disease","volume":"6","author":"Bao","year":"2021","journal-title":"JCI Insight."},{"issue":"1","key":"B45-20260910","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41598-018-37690-5","article-title":"Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212","volume":"9","author":"S\u00e1rk\u00f6zy","year":"2019","journal-title":"Sci Rep."},{"issue":"1","key":"B46-20260910","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.121.001251","article-title":"Empagliflozin improves the MicroRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes","volume":"384","author":"Mone","year":"2023","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"B47-20260910","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.kint.2017.05.014","article-title":"MicroRNA-21 regulates peroxisome proliferator\u2013activated receptor alpha, a molecular mechanism of cardiac pathology in cardiorenal syndrome type 4","volume":"93","author":"Chuppa","year":"2018","journal-title":"Kidney Int."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:00:52Z","timestamp":1789056052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001002","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}